Cerebrolysin's '15 clinical applications': separating real data from TikTok hype

What's this video probably claiming?

Based on the caption's numbered list structure and the hashtag cloud, @projectbiohackedjeff is almost certainly walking through a slide-style breakdown of cerebrolysin as a broad-spectrum neurological intervention. The framing, "top 15 clinical applications," signals confidence well beyond what the evidence supports. The hashtags tell the fuller story: this content is being served to audiences searching for TBI recovery, CIRS (chronic inflammatory response syndrome), ADHD treatment, and mold illness, which means the creator is likely positioning cerebrolysin as applicable to a remarkably wide range of conditions simultaneously. Cerebrolysin is a porcine brain-derived peptide mixture containing neurotrophic factors and amino acids. It is approved and used clinically in parts of Europe and Asia, particularly for stroke and dementia. It is not FDA-approved in the United States. Any creator framing this as having 15 documented clinical applications for a general consumer audience is doing significant work that the regulatory and clinical record simply does not support.

What does the science actually show?

The honest answer is: mixed, context-dependent, and nowhere near settled. The best evidence for cerebrolysin comes from acute ischemic stroke, where a 2019 Cochrane review (Chen et al.) analyzed 55 trials involving over 8,600 patients and found cerebrolysin at doses of 30-50ml IV improved short-term neurological function scores, but the reviewers rated overall evidence quality as low to moderate due to trial heterogeneity and unclear blinding. A 2021 RCT (Bornstein et al., Stroke) using 30ml daily for 10 days showed statistically significant improvement in mRS scores at 90 days compared to placebo. For TBI, the CAPTAIN trial (Muresanu et al., 2020, CNS Drugs) showed improvements in GCS and GOS-E scores in moderate-to-severe TBI patients given 30ml IV daily for 10 days. That is a hospital-administered, acute-care protocol, not a peptide therapy program. For Alzheimer's disease, small trials show signal, but the 2019 Cochrane review (Feng et al.) found only modest short-term cognitive benefits with high drop-out rates. For ADHD, mold illness, and CIRS, there is essentially no controlled trial data.

Where does the social media noise diverge from clinical reality?

Several gaps here are worth naming directly. First, virtually all positive cerebrolysin trials use IV administration at 10-30ml doses in acute or subacute clinical settings. The biohacking community largely sources this as a subcutaneous injectable purchased from compounding pharmacies or gray-market suppliers, which is a meaningfully different pharmacokinetic situation. There are no controlled trials validating subcutaneous cerebrolysin dosing regimens for any indication. Second, the hashtag use of moldillness and cirsrecovery is a red flag. CIRS is itself a contested diagnostic framework, and applying cerebrolysin to it represents several inferential leaps stacked on top of each other. Third, the "15 clinical applications" framing implies an equivalence across conditions that does not exist. Stroke recovery has moderate trial evidence. ADHD has none. Presenting them in the same numbered list misleads viewers about confidence levels. The Cochrane reviewers were explicit that most trials had methodological limitations that prevent strong conclusions even in the best-studied populations.

What should you actually know?

Cerebrolysin is not a fringe compound. It has a real pharmacological profile and legitimate clinical research behind it, particularly for stroke and TBI in acute care settings. But the version being discussed in biohacking content is rarely the version studied in trials. Buyers sourcing this outside regulated clinical pathways are working without verified purity, without validated dosing for their route of administration, and without the monitoring that accompanied every trial that produced positive results. The compound carries a risk of allergic reactions and, in higher doses, adverse neurological effects. More practically, the populations seeing the most benefit in trials are acute hospital patients, not people self-administering months after injury onset. If you have had a TBI, stroke, or are managing cognitive decline, the evidence-based path is working with a neurologist who can assess whether a trial-validated protocol applies to your situation. No TikTok format, however well-produced, can replace that evaluation. Cerebrolysin does not cure any disease, and no responsible reading of current evidence suggests it should be self-administered outside clinical supervision.